Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 10/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 10/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3589696 | 0.90 | DDB1 (0.33) | PDE3BPDE3ADDB1CRBNPKM | |
| SCHEMBL3597785 | 0.85 | PDE3B (0.36) | PDE3BPDE3AEPHX2PDE4APDE4B | |
| SCHEMBL3601168 | 0.83 | BRD4 (0.30) | DDB1CRBN | |
| SCHEMBL3589697 | 0.78 | CA9 (0.40) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL3598575 | 0.76 | HSP90AA1 (0.33) | GAAMAPT | |
| SCHEMBL3584555 | 0.76 | DDB1 (0.36) | DDB1CRBNPARP1GAAMAPT | |
| SCHEMBL3600255 | 0.76 | TRPV1 (0.31) | DDB1CRBNPARP1 | |
| SCHEMBL13382926 | 0.76 | S1PR1 (0.35) | PDE3BPDE3ADDB1CRBNS1PR1 | |
| SCHEMBL3605980 | 0.75 | TRPV1 (0.39) | DDB1CRBN | |
| SCHEMBL3597334 | 0.75 | DDB1 (0.35) | DDB1CRBNGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-2128157-A1 | HETEROCYCLIDENE-N-(ARYL)ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | CCNY, CCND3, NSD3 | PDE3B 3066/4885PDE3A 2554/4885EPHX2 1258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.